ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
ScripThe recent American College of Cardiology (ACC) conference should have provided companies with the chance to share positive trial updates and saunter into the next trading week with bolstered stock pr
ScripOne of Sanofi’s hoped-for respiratory blockbusters, amlitelimab, has stumbled after disappointing results in a Phase II asthma study. Preliminary results from the TIDE-Asthma Phase II study showed tha
Pink SheetDespite the ongoing upheaval across the agency, the US Food and Drug Administration maintained its typical reliability when it came to meeting user fee goal dates in the first quarter of 2025, the Pi